Dr. Herriot Tabuteau M.D. serves as Chairman of the Board, President, Chief Executive Officer, Founder of the Company. Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. He is also the founder of Antecip Capital LLC (formerly Versant Capital Management LLC), one of our principal stockholders, for which Dr. Tabuteau has been the managing member since 2003. Dr. Tabuteau is also the managing member of Antecip Bioventures II LLC. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.
As the Chairman of the Board, President, Chief Executive Officer, and Founder of Axsome Therapeutics Inc, the total compensation of Herriot Tabuteau at Axsome Therapeutics Inc is $4,715,750. There are no executives at Axsome Therapeutics Inc getting paid more.
Herriot Tabuteau is 51, he's been the Chairman of the Board, President, Chief Executive Officer, and Founder of Axsome Therapeutics Inc since 2018. There are 3 older and 10 younger executives at Axsome Therapeutics Inc. The oldest executive at Axsome Therapeutics Inc is David Marek, 55, who is the Chief Commercial Officer.
Herriot's mailing address filed with the SEC is 25 Broadway, New York, NY 10004, USA.
Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony, and Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
Axsome Therapeutics Inc executives and other stock owners filed with the SEC include: